NCT01713348

Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: Abbott Diabetes Care · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To understand if Multiple Daily Injections (MDI) managed subjects can improve glycaemic control by; 1. regularly checking and understanding Continuous Glucose data \& trend arrows at times other than the standard pre-meal bolus calculation test times and 2. review of their glucose profiles (inc. hypoglycaemic risks) with their Health Care Professional (HCP) and adjusting behaviours \& therapy from interpretation of the Continuous Glucose profiles.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DEVICE	FreeStyle Navigator	Masked CGM day 1 to 15, unmasked CGM days 15 to 100
DEVICE	Standard SMBG	Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-05-01
• Completion: 2013-07-01
• First posted: 2012-10-24
• Last updated: 2016-03-04
• Results posted: 2015-03-11

Locations

9 sites across 1 country: United Kingdom